JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Raises Price Target to $101
JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and raises the price target from $91 to $101.
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
Beam Therapeutics Inc (NASDAQ:BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ:APLS) to create new gene-editing treatments for complement-driven diseases. The partnership will…
Apellis Pharma Reports Exclusive Research Collab With Beam Therapeutics To Apply Base Editing To Discover Novel Therapies For Complement-Driven Diseases
Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing platform
Companies will collaborate on six research programs directed to tissues
Needham Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $85
Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $65 to $85.
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 24)
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET on Thursday, 145 companies set new 52-week highs.
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 15)
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 125 stocks hit new 52-week highs.
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 14)